EE183 Cost per Responder Analysis of Bimekizumab, a Monoclonal IgG1 Antibody Which Selectively Inhibits Il17f in Addition to Il17a Against Il17a Inhibitors in the Treatment of Axial Spondyloarthritis in Finland
Abstract
Authors
Lauri Veijalainen Petri Juhani Kristian Elo Fredrik Borgström Adam Ferguson Michael Frank Mørup